Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566435 | 0.86 | PPARG (0.61) | FOLH1PPARGPTGESALOX5PPARA | |
| SCHEMBL5054549 | 0.79 | FOLH1 (0.73) | FOLH1PPARGPPARA | |
| SCHEMBL5057853 | 0.76 | FOLH1 (0.72) | FOLH1PPARGPTGESALOX5PPARA | |
| SCHEMBL121365 | 0.76 | FOLH1 (0.53) | FOLH1PPARGPTGESALOX5PPARA | |
| SCHEMBL1565567 | 0.76 | PPARG (0.61) | FOLH1PPARGPTGESALOX5PPARA | |
| SCHEMBL5057796 | 0.76 | FOLH1 (0.60) | FOLH1PPARGPPARA | |
| SCHEMBL5053326 | 0.76 | FOLH1 (0.80) | FOLH1PPARGPTGESALOX5PPARA | |
| SCHEMBL5059904 | 0.76 | FOLH1 (0.63) | FOLH1PPARGPTGESALOX5PPARA | |
| SCHEMBL5054619 | 0.75 | FOLH1 (0.72) | FOLH1PPARGPPARAKMT2AMAPK1 | |
| SCHEMBL5053092 | 0.75 | FOLH1 (1.00) | FOLH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812364-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; ANTICANCER AGENTS | GUILFORD PHARMACEUTICALS INC. | 2004-11-02 | — | — | US | claimed |
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6812364-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; ANTICANCER AGENTS | GUILFORD PHARMACEUTICALS INC. | 2004-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885PPARG 3596/4885PTGES 298/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885PPARG 751/4885PTGES 4094/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885PPARG 3596/4885PTGES 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.